ArticleJournal of pain research2013
In vitro pharmacological characterization of a novel TRPA1 antagonist and proof of mechanism in a human dental pulp model.
Article in Journal of pain research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 32 citations in OpenAlex.
- A TRPA1 inhibitor suppresses neurogenic inflammation and airway contraction for asthma treatment.The Journal of experimental medicine · 2021Trial
- Evaluated periodontal tissues and oxidative stress in rats with neuropathic pain-like behavior.Molecular biology reports · 2023Article
- Discovery ofJournal of medicinal chemistry · 2023Article
- Evaluation of analgesic and anti-inflammatory activity of purine-2,6-dione-based TRPA1 antagonists with PDE4/7 inhibitory activity.Pharmacological reports : PR · 2022Article
- Modulators of Transient Receptor Potential (TRP) Channels as Therapeutic Options in Lung Disease.Pharmaceuticals (Basel, Switzerland) · 2019Review
- Oxidative stress in patients with endodontic pathologies.Journal of pain research · 2017Article
- Involvement of TRPA1 in the cinnamaldehyde-induced pulpal blood flow change in the feline dental pulp.Restorative dentistry & endodontics · 2016Article
- Variability in Capsaicin-stimulated Calcitonin Gene-related Peptide Release from Human Dental Pulp.Journal of endodontics · 2016Article
- How Far Have We Come in the Field of Nerve Regeneration After Trigeminal Nerve Injury?Current oral health reports · 2016Review
- Potency of irritation by benzylidenemalononitriles in humans correlates with TRPA1 ion channel activation.Royal Society open science · 2015Article
- Transient receptor potential (TRP) channels: a clinical perspective.British journal of pharmacology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AZ465 is a novel selective transient receptor potential cation channel, member A1 (TRPA1) antagonist identified during a focused drug discovery effort. In vitro, AZ465 fully inhibits activation by zinc, O-chlorobenzylidene malononitrile (CS), or cinnamaldehyde of the human TRPA1 channel heterologously expressed in human embryonic kidney cells. Our data using patch-clamp recordings and mouse/human TRPA1 chimeras suggest that AZ465 binds reversibly in the pore region of the human TRPA1 channel. Finally, in an ex vivo model measuring TRPA1 agonist-stimulated release of neuropeptides from human dental pulp biopsies, AZD465 was able to block 50%-60% of CS-induced calcitonin gene-related peptide release, confirming that AZ465 inhibits the native human TRPA1 channel in neuronal tissue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.